Literature DB >> 34035482

LncRNA MAFG-AS1 promotes the malignant phenotype of ovarian cancer by upregulating NFKB1-dependent IGF1.

Yang Bai1, Chenchen Ren1, Baojin Wang1, Jingge Xue1, Feiyan Li1, Jiaxi Liu1, Li Yang2.   

Abstract

Long non-coding RNAs (lncRNAs) were recently recognized to vitally function in a variety of cancer cellular events, including epithelial-mesenchymal transition (EMT), invasion, and migration, particularly in ovarian cancer (OC). Herein, we sought to investigate the potential role of MAFG-AS1 in the malignant behaviors of OC cells. The binding affinity between MAFG-AS1, miR-339-5p, NFKB1 or IGF1 was characterized so as to identify the underlying mechanism of corresponding their interactions. We conducted MAFG-AS1 overexpression or knockdown along with NFKB1 and IGF1 silencing to examine their effects on the EMT, migration, and invasion of OC cells. Tumors were xenografted in nude mice to validate the in vitro findings. Our data showed significantly high expression pattern of MAFG-AS1 in the OC tissues and cells. Further mechanistic investigations revealed that MAFG-AS1 upregulated the IGF1 expression pattern through recruitment of NFKB1, whereas MAFG-AS1 upregulated the NFKB1 expression pattern through binding to miR-339-5p. Thus, MAFG-AS1 overexpression accelerated the EMT, invasion, and migration of OC cells, which could be annulled by silencing of IGF1 or NFKB1. Besides, our in vitro findings were successfully recapitulated in the xenograft mice. These results determined that MAFG-AS1 stimulated the OC malignant progression by upregulating the NFKB1-mediated IGF1 via miR-339-5p, thus highlighting a novel potential therapeutic target against OC.
© 2021. The Author(s), under exclusive licence to Springer Nature America, Inc. part of Springer Nature.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34035482     DOI: 10.1038/s41417-021-00306-8

Source DB:  PubMed          Journal:  Cancer Gene Ther        ISSN: 0929-1903            Impact factor:   5.987


  37 in total

Review 1.  lncRNAs: insights into their function and mechanics in underlying disorders.

Authors:  Xiaolei Li; Zhiqiang Wu; Xiaobing Fu; Weidong Han
Journal:  Mutat Res Rev Mutat Res       Date:  2014-05-09       Impact factor: 5.657

Review 2.  Ovarian cancer.

Authors:  Ursula A Matulonis; Anil K Sood; Lesley Fallowfield; Brooke E Howitt; Jalid Sehouli; Beth Y Karlan
Journal:  Nat Rev Dis Primers       Date:  2016-08-25       Impact factor: 52.329

3.  Super-Enhancer-Associated Long Noncoding RNA HCCL5 Is Activated by ZEB1 and Promotes the Malignancy of Hepatocellular Carcinoma.

Authors:  Li Peng; Binyuan Jiang; Xiaoqing Yuan; Yuntan Qiu; Jiangyun Peng; Yongsheng Huang; Chaoyang Zhang; Yin Zhang; Zhaoyu Lin; Jinsong Li; Weicheng Yao; Weixi Deng; Yaqin Zhang; Meng Meng; Xi Pan; Chunquan Li; Dong Yin; Xinyu Bi; Guancheng Li; De-Chen Lin
Journal:  Cancer Res       Date:  2018-11-27       Impact factor: 12.701

4.  LncRNA MAFG-AS1 facilitates the migration and invasion of NSCLC cell via sponging miR-339-5p from MMP15.

Authors:  You Chao Jia; Jian Yi Wang; Yu Ying Liu; Bin Li; Hui Guo; Ai Min Zang
Journal:  Cell Biol Int       Date:  2019-02-06       Impact factor: 3.612

5.  LncRNA PTAR promotes EMT and invasion-metastasis in serous ovarian cancer by competitively binding miR-101-3p to regulate ZEB1 expression.

Authors:  Haihai Liang; Tong Yu; Yue Han; Hua Jiang; Chengyu Wang; Tianyi You; Xiaoguang Zhao; Huitong Shan; Rui Yang; Lida Yang; Hongli Shan; Yunyan Gu
Journal:  Mol Cancer       Date:  2018-08-11       Impact factor: 27.401

6.  HOXD-AS1 promotes the epithelial to mesenchymal transition of ovarian cancer cells by regulating miR-186-5p and PIK3R3.

Authors:  Shanshan Dong; Ranran Wang; Hui Wang; Qi Ding; Xiao Zhou; Jing Wang; Keqiang Zhang; Ying Long; Shan Lu; Ting Hong; Huayi Ren; Kee Wong; Xiaowu Sheng; Yu Wang; Yong Zeng
Journal:  J Exp Clin Cancer Res       Date:  2019-03-01

7.  LncRNA FLVCR1-AS1 mediates miR-513/YAP1 signaling to promote cell progression, migration, invasion and EMT process in ovarian cancer.

Authors:  Huan Yan; Hong Li; Maria A Silva; Yichun Guan; Li Yang; Linlin Zhu; Zhan Zhang; Genxia Li; Chenchen Ren
Journal:  J Exp Clin Cancer Res       Date:  2019-08-14

8.  LncRNA TUG1 promoted KIAA1199 expression via miR-600 to accelerate cell metastasis and epithelial-mesenchymal transition in colorectal cancer.

Authors:  Junfeng Sun; Jiyi Hu; Guojun Wang; Zhen Yang; Chunlin Zhao; Xiefu Zhang; Jiaxiang Wang
Journal:  J Exp Clin Cancer Res       Date:  2018-05-18

9.  Long noncoding RNA MLK7-AS1 promotes ovarian cancer cells progression by modulating miR-375/YAP1 axis.

Authors:  Huan Yan; Hong Li; Pengyun Li; Xia Li; Jianjian Lin; Linlin Zhu; Maria A Silva; Xiaofang Wang; Ping Wang; Zhan Zhang
Journal:  J Exp Clin Cancer Res       Date:  2018-09-24

10.  Long non-coding RNA TPT1-AS1 promotes cell growth and metastasis in cervical cancer via acting AS a sponge for miR-324-5p.

Authors:  Hui Jiang; Guanqun Huang; Nianzhang Zhao; Ting Zhang; Mengni Jiang; Yueming He; Xinke Zhou; Xianhan Jiang
Journal:  J Exp Clin Cancer Res       Date:  2018-07-25
View more
  3 in total

1.  5-Methylcytosine RNA Methyltransferases-Related Long Non-coding RNA to Develop and Validate Biochemical Recurrence Signature in Prostate Cancer.

Authors:  Ke Wang; Weibo Zhong; Zining Long; Yufei Guo; Chuanfan Zhong; Taowei Yang; Shuo Wang; Houhua Lai; Jianming Lu; Pengxiang Zheng; Xiangming Mao
Journal:  Front Mol Biosci       Date:  2021-12-01

2.  CircESRP1 enhances metastasis and epithelial-mesenchymal transition in endometrial cancer via the miR-874-3p/CPEB4 axis.

Authors:  Rui Shi; Wei Zhang; Jun Zhang; Zhicheng Yu; Lanfen An; Rong Zhao; Xing Zhou; Ziwei Wang; Sitian Wei; Hongbo Wang
Journal:  J Transl Med       Date:  2022-03-22       Impact factor: 5.531

3.  Long Non-Coding RNA MAFG-AS1 as a Potential Biomarker for Hepatocellular Carcinoma: Linkage with Tumor Features, Markers, Liver Functions, and Survival Profile.

Authors:  Yuanyuan Tian; Jiao Wang; Ge Tian; Bing Li; Moli Chen; Xiaoning Sun
Journal:  Front Surg       Date:  2022-05-17
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.